Exendin-4 effects on islet volume and number in the mouse pancreas

Area of Science:

• Endocrinology
• Pancreatic Biology
• Pharmacology

Background:

• Exendin-4 (EX-4) is a glucagon-like peptide-1 receptor agonist.
• Understanding EX-4's impact on pancreatic islet morphology is crucial for diabetes research.

Purpose of the Study:

• To investigate the effects of varying Exendin-4 doses on pancreatic islet volume and number in healthy mice.
• To determine if EX-4 promotes islet neogenesis or hypertrophy.

Main Methods:

• Healthy adult male NMRI mice were administered Exendin-4 (0.25, 0.5, or 1 μg/kg) intraperitoneally twice daily for seven days.
• Pancreas weight, islet volume, and islet number were measured using stereological assessments after sacrifice.
• Statistical analysis compared experimental groups to a control group.

Main Results:

• A significant increase in pancreas weight was observed in the highest EX-4 dose group (1 μg/kg).
• The highest EX-4 dose significantly increased both pancreas and islet volume (p < 0.05).
• No significant changes in the total number of islets were found across any experimental groups.

Conclusions:

• Exendin-4 administration, particularly at higher doses, promotes pancreatic islet and overall pancreas enlargement in non-diabetic mice.
• The observed increase in islet mass is attributed to hypertrophy (enlargement of existing islets) rather than neogenesis (formation of new islets).
• These findings suggest EX-4's potential role in modulating pancreatic tissue mass through cellular hypertrophy.